AR112760A1 - Compuestos bifuncionales que comprenden un análogo de glp-1 y un análogo de egf(a) - Google Patents
Compuestos bifuncionales que comprenden un análogo de glp-1 y un análogo de egf(a)Info
- Publication number
- AR112760A1 AR112760A1 ARP180102028A ARP180102028A AR112760A1 AR 112760 A1 AR112760 A1 AR 112760A1 AR P180102028 A ARP180102028 A AR P180102028A AR P180102028 A ARP180102028 A AR P180102028A AR 112760 A1 AR112760 A1 AR 112760A1
- Authority
- AR
- Argentina
- Prior art keywords
- glp
- analogue
- analog
- egf
- compounds including
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 3
- 230000001588 bifunctional effect Effects 0.000 title 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 abstract 1
- 229940122392 PCSK9 inhibitor Drugs 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 abstract 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
La solicitud divulga compuestos útiles en el tratamiento de diabetes, pérdida de peso y/o reducción de riesgos cardiovasculares. Los compuestos son bi-funcionales, y por lo tanto, adecuados como un tratamiento simple para pacientes que pueden beneficiarse del tratamiento tanto con un agonista del receptor GLP-1 como con un inhibidor PCSK9. Reivindicación 1: Un compuesto que comprende un análogo de GLP-1 y un análogo de EGF(A), donde i) dicho análogo de GLP-1 es un análogo de GLP-1(7-37) identificado por SEQ ID Nº 137, y ii) dicho análogo de EGF(A) es un análogo del dominio de EGF(A) de LDL-R(293-332) identificado por SEQ ID Nº 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17182010 | 2017-07-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR112760A1 true AR112760A1 (es) | 2019-12-11 |
Family
ID=59383423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180102028A AR112760A1 (es) | 2017-07-19 | 2018-07-19 | Compuestos bifuncionales que comprenden un análogo de glp-1 y un análogo de egf(a) |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11130794B2 (es) |
| EP (1) | EP3655427A1 (es) |
| JP (1) | JP7339236B2 (es) |
| KR (1) | KR20200037793A (es) |
| CN (1) | CN110945017B (es) |
| AR (1) | AR112760A1 (es) |
| AU (1) | AU2018303625A1 (es) |
| BR (1) | BR112020001286A2 (es) |
| CA (1) | CA3068956A1 (es) |
| CL (1) | CL2020000166A1 (es) |
| CO (1) | CO2020001012A2 (es) |
| IL (1) | IL272006A (es) |
| MA (1) | MA49621A (es) |
| PE (1) | PE20200720A1 (es) |
| TW (1) | TW201918494A (es) |
| WO (1) | WO2019016306A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3402811B1 (en) | 2016-01-13 | 2022-03-30 | Novo Nordisk A/S | Egf(a) analogues with fatty acid substituents |
| CN110357969B (zh) * | 2019-05-27 | 2022-03-08 | 北京志道生物科技有限公司 | 一种GLP1-EGFa异源二聚体蛋白、功能及方法 |
| WO2021136223A1 (en) | 2019-12-31 | 2021-07-08 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion proteins of glp-1 and gdf15 and conjugates thereof |
| CN114729060B (zh) | 2020-09-30 | 2022-11-25 | 北京质肽生物医药科技有限公司 | 多肽缀合物和使用方法 |
| CN116410297A (zh) * | 2021-07-19 | 2023-07-11 | 内蒙古博睿精创科技有限公司 | 长效glp-1多肽类似物及其制备方法和应用 |
| US20250154203A1 (en) * | 2022-02-17 | 2025-05-15 | Revolo Biotherapeutics Limited | Method of producing peptide derived from chaperonin 60.1 |
| KR20240163717A (ko) | 2022-03-30 | 2024-11-19 | 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 | 폴리펩티드 접합체의 액체 약학 조성물 및 그의 사용 방법 |
| CN120731085A (zh) * | 2023-03-02 | 2025-09-30 | 甘李药业股份有限公司 | 一种glp-1化合物的医药用途 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2428510T3 (es) | 2005-02-02 | 2013-11-08 | Novo Nordisk A/S | Derivados de insulina |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| WO2007018619A2 (en) | 2005-07-29 | 2007-02-15 | Amprotein Corporation | Chimeric therapeutic agents |
| AU2006279680B2 (en) | 2005-08-11 | 2012-12-06 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
| US20100029903A1 (en) * | 2005-12-14 | 2010-02-04 | Novo Nordisk A/S | Polypeptide Protracting Tags |
| KR20100058509A (ko) * | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| JP5721432B2 (ja) | 2007-08-15 | 2015-05-20 | ノボ・ノルデイスク・エー／エス | アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン |
| ES2532116T3 (es) * | 2007-09-05 | 2015-03-24 | Novo Nordisk A/S | Péptidos derivados con A-B-C-D y sus usos terapéuticos |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| CA2720681C (en) | 2008-04-23 | 2016-08-02 | Amgen Inc. | Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof |
| WO2009143633A1 (en) | 2008-05-30 | 2009-12-03 | Institut De Recherches Cliniques De Montreal | Pcsk9 inhibitors and methods of use thereof |
| CN102149411A (zh) | 2008-09-12 | 2011-08-10 | 诺沃—诺迪斯克有限公司 | 酰化肽或蛋白的方法 |
| TWI445716B (zh) | 2008-09-12 | 2014-07-21 | Rinat Neuroscience Corp | Ｐｃｓｋ９拮抗劑類 |
| WO2010102886A1 (en) | 2009-02-19 | 2010-09-16 | Novo Nordisk A/S | Modification of factor viii |
| CN101993485B (zh) | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | 促胰岛素分泌肽类似物同源二聚体及其用途 |
| CN102153652A (zh) | 2010-12-10 | 2011-08-17 | 浙江大学 | 一种融合蛋白的表达方法及用途 |
| EP2675470A1 (en) | 2011-02-15 | 2013-12-25 | Novo Nordisk A/S | Long-acting il-1 receptor antagonists |
| BR112013032667A2 (pt) | 2011-06-20 | 2017-12-12 | Genentech Inc | polipeptídeo de ligação a pcsk9, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o polipeptídeo, composição farmacêutica, método de redução do nível de colesterol ldl em um sujeito, método de tratamento de disfunção relacionada ao colesterol em um sujeito, método de tratamento de hipercolesterolemia em um sujeito, método de inibição da ligação de pcsk9 a ldlr e método de detecção da proteína pcsk9 em uma amostra |
| MY167234A (en) | 2011-09-23 | 2018-08-14 | Novo Nordisk As | Novel glucagon analogues |
| US9458214B2 (en) | 2011-09-26 | 2016-10-04 | Novartis Ag | Dual function fibroblast growth factor 21 proteins |
| EP2794648A1 (en) | 2011-12-21 | 2014-10-29 | Novo Nordisk A/S | N-terminally modified insulin derivatives |
| CN104011064A (zh) | 2011-12-29 | 2014-08-27 | 诺沃—诺迪斯克有限公司 | 包含非成蛋白质性的氨基酸的二肽 |
| CN104302772B (zh) | 2012-05-18 | 2017-11-10 | 爱德迪安（北京）生物技术有限公司 | 用于糖尿病治疗的蛋白、蛋白缀合物及其应用 |
| TW201420606A (zh) | 2012-08-22 | 2014-06-01 | Lilly Co Eli | 同源二聚體蛋白 |
| KR20150043505A (ko) | 2012-09-07 | 2015-04-22 | 사노피 | 대사 증후군의 치료용 융합 단백질 |
| SG11201503526UA (en) * | 2012-12-21 | 2015-06-29 | Sanofi Sa | Dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| WO2014170496A1 (en) | 2013-04-18 | 2014-10-23 | Novo Nordisk A/S | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
| AR096789A1 (es) | 2013-07-04 | 2016-02-03 | Novo Nordisk As | Derivados de péptidos similares a glp-1 y usos de los mismos |
| WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| KR20160124787A (ko) | 2014-02-21 | 2016-10-28 | 메디뮨 엘엘씨 | 항-pcsk9∼glp-1 융합체 및 사용 방법 |
| WO2015185640A1 (en) | 2014-06-04 | 2015-12-10 | Novo Nordisk A/S | Glp-1/glucagon receptor co-agonists for medical use |
| CN104558198A (zh) | 2014-07-25 | 2015-04-29 | 成都贝爱特生物科技有限公司 | GLP-1类似物和amylin类似物的融合蛋白制备及其用途 |
| EP3271379A4 (en) | 2015-03-19 | 2018-08-01 | Institut de Cardiologie de Montréal | Grp94 derived polypeptides for inhibiting pcsk9 and methods of use |
| CN105367884A (zh) | 2015-11-02 | 2016-03-02 | 陈薇 | 一种绝缘耐火抗辐射的屏蔽电缆材料及其制备方法 |
| EP3402811B1 (en) | 2016-01-13 | 2022-03-30 | Novo Nordisk A/S | Egf(a) analogues with fatty acid substituents |
| MA49617A (fr) | 2017-07-19 | 2020-05-27 | Novo Nordisk As | Analogues d'egf(a), préparation, formulations et utilisations associées |
-
2018
- 2018-07-19 AU AU2018303625A patent/AU2018303625A1/en not_active Abandoned
- 2018-07-19 CN CN201880048047.1A patent/CN110945017B/zh active Active
- 2018-07-19 AR ARP180102028A patent/AR112760A1/es unknown
- 2018-07-19 MA MA049621A patent/MA49621A/fr unknown
- 2018-07-19 CA CA3068956A patent/CA3068956A1/en not_active Withdrawn
- 2018-07-19 PE PE2020000085A patent/PE20200720A1/es unknown
- 2018-07-19 WO PCT/EP2018/069610 patent/WO2019016306A1/en not_active Ceased
- 2018-07-19 TW TW107124975A patent/TW201918494A/zh unknown
- 2018-07-19 US US16/632,007 patent/US11130794B2/en active Active
- 2018-07-19 BR BR112020001286-6A patent/BR112020001286A2/pt not_active IP Right Cessation
- 2018-07-19 KR KR1020207003735A patent/KR20200037793A/ko not_active Withdrawn
- 2018-07-19 JP JP2020500190A patent/JP7339236B2/ja active Active
- 2018-07-19 EP EP18740854.7A patent/EP3655427A1/en active Pending
-
2020
- 2020-01-13 IL IL272006A patent/IL272006A/en unknown
- 2020-01-17 CL CL2020000166A patent/CL2020000166A1/es unknown
- 2020-01-28 CO CONC2020/0001012A patent/CO2020001012A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110945017A (zh) | 2020-03-31 |
| CN110945017B (zh) | 2024-07-16 |
| CL2020000166A1 (es) | 2020-06-12 |
| CA3068956A1 (en) | 2019-01-24 |
| US11130794B2 (en) | 2021-09-28 |
| WO2019016306A1 (en) | 2019-01-24 |
| AU2018303625A1 (en) | 2020-02-06 |
| US20200231645A1 (en) | 2020-07-23 |
| JP2020528049A (ja) | 2020-09-17 |
| CO2020001012A2 (es) | 2020-02-18 |
| KR20200037793A (ko) | 2020-04-09 |
| TW201918494A (zh) | 2019-05-16 |
| MA49621A (fr) | 2020-05-27 |
| EP3655427A1 (en) | 2020-05-27 |
| BR112020001286A2 (pt) | 2020-07-28 |
| JP7339236B2 (ja) | 2023-09-05 |
| PE20200720A1 (es) | 2020-07-21 |
| IL272006A (en) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR112760A1 (es) | Compuestos bifuncionales que comprenden un análogo de glp-1 y un análogo de egf(a) | |
| CL2022001271A1 (es) | Agonista del receptor glp-1 y uso de este | |
| AR102712A1 (es) | Agonistas parciales del receptor de insulina | |
| CO2022010241A2 (es) | Inhibidores de sos1 | |
| PE20210162A1 (es) | Analogos de incretina y sus usos | |
| DOP2022000172A (es) | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd) | |
| UY38428A (es) | Nuevos compuestos antihelmínticos | |
| ECSP19046893A (es) | Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip | |
| CL2016001911A1 (es) | Compuesto heterocíclico fusionado | |
| MX2019008337A (es) | Uso de cannabinoides para el tratamiento de epilepsia. | |
| NI201700042A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos. | |
| CL2017001760A1 (es) | Compuestos co-agonistas de gip y glp-1 | |
| CR10991A (es) | Compuestos anulares fusionados como antagonistas parciales de ppar-gamma | |
| MX2016016236A (es) | Anticuerpos dirigidos contra cd127. | |
| AR061230A1 (es) | Prolongacion de la supervivencia de pacientes con cancer con niveles elevados de egf o tgf-alfa | |
| CL2011002494A1 (es) | Compuestos derivados de 7-aza-di-espiro-[3.0.4.1]-decan-8-carboxamida; composición farmacéutica que los comprenden; y uso para el tratamiento de un trastorno asociado con el virus de la hepatitis c (hcv) y el virus de inmunodeficiencia humana (vih). | |
| UY37564A (es) | Aislados de lysinibacillus y usos de los mismos | |
| UY37589A (es) | COMPUESTOS MODULADORES DEL RECEPTOR DE HIDROCARBUROS ARÍLICOS (AhR) | |
| CL2021003266A1 (es) | Anticuerpos de receptor de péptido natriurético 1 y métodos de uso | |
| CO2017009930A2 (es) | Formulacion de combinacion de tesofensina y betabloqueante | |
| CL2020002165A1 (es) | Uso de tradipitant para tratar la cinetosis. | |
| MX2024000276A (es) | Analogo de peptido de oxintomodulina acilado. | |
| CL2009001012A1 (es) | Un metodo para el tratamiento de una condicion dependiente de progesterona que comprende el uso de una composicion que comprende una antiprogestina 19-noresteroide que contiene un anillo fenilo sustituido con monometilamina en la posicion 11 beta del carbono 11. | |
| CL2019003325A1 (es) | Uso novedoso de un agonista del receptor 2 de formil péptido / receptor a4de lipoxina (fpr2 / alx) para el tratamiento de la insuficiencia cardíaca. | |
| CL2020000482A1 (es) | Composición para la estimulación ovárica controlada. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |